About Pierian
Pierian is a precision medicine technology company that develops clinical genomics interpretation and reporting software for healthcare organizations, laboratories, and research institutions. The company's flagship product, Clinical Genomics Workspace (CGW), is a comprehensive platform designed to streamline the analysis and interpretation of genomic data for oncology and rare disease applications. Pierian's software enables clinical laboratories to transform complex genomic sequencing data into actionable clinical reports that support precision medicine decision-making. The platform integrates advanced bioinformatics tools with clinical knowledge bases to help genomic specialists identify clinically relevant variants, assess their significance, and generate reports that meet regulatory and clinical standards. Pierian serves molecular diagnostic laboratories, academic medical centers, hospital systems, and pharmaceutical companies involved in genomic testing and precision oncology. The company's technology addresses the growing need for scalable, efficient genomic interpretation solutions as next-generation sequencing becomes increasingly integrated into routine clinical care. By automating portions of the interpretation workflow while maintaining clinical oversight, Pierian helps organizations increase throughput, reduce turnaround times, and improve consistency in genomic reporting.
Clinical Focus
Medical conditions and clinical areas addressed by Pierian.
Who It Serves
Milestones & Awards
Recent Milestones
Company rebranded from PierianDx to Pierian
Social & Media
Follow on
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.